Total Payments
$87,163
2024 Payments
$50,810
Companies
18
Transactions
105
Medicare Patients
21,880
Medicare Billing
$7.1M
Payment Breakdown by Category
Other$82,383 (94.5%)
Food & Beverage$4,742 (5.4%)
Gifts$38.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $50,000 | 1 | 57.4% |
| Current or prospective ownership or investment interest | $32,383 | 6 | 37.2% |
| Food and Beverage | $4,742 | 88 | 5.4% |
| Gift | $38.80 | 2 | 0.0% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$87,163
97 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $82,825 | 17 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,049 | 29 | $0 (2024) |
| Genentech USA, Inc. | $519.44 | 19 | $0 (2024) |
| Allergan, Inc. | $483.20 | 9 | $0 (2021) |
| Dutch Ophthalmic, USA | $469.86 | 3 | $0 (2022) |
| Alimera Sciences, Inc. | $440.70 | 2 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $433.04 | 3 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $262.38 | 2 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $175.66 | 5 | $0 (2019) |
| ABBVIE INC. | $173.13 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,810 | 15 | US Retina LLC ($50,000) |
| 2023 | $334.26 | 11 | Bausch & Lomb Americas Inc. ($111.27) |
| 2022 | $10,496 | 10 | US Retina LLC ($10,071) |
| 2021 | $15,211 | 6 | US Retina LLC ($15,003) |
| 2020 | $3,519 | 6 | US Retina LLC ($3,353) |
| 2019 | $5,325 | 19 | US Retina LLC ($4,398) |
| 2018 | $621.05 | 14 | Regeneron Healthcare Solutions, Inc. ($302.31) |
| 2017 | $846.21 | 24 | Regeneron Healthcare Solutions, Inc. ($344.11) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: EYE CARE | ||||||
| 12/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $154.24 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/22/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/10/2024 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $50,000.00 | General |
| 09/03/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $315.70 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/29/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: EYE CARE | ||||||
| 07/25/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $31.77 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Ophthalmology | ||||||
| 07/01/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $168.54 | General |
| Category: Ophthalmology | ||||||
| 04/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $7.94 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $0.92 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $0.56 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $31.47 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/20/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $33.14 | General |
| Category: Immunology and Ophthalmology | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 11/15/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: EYE CARE | ||||||
| 08/22/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $33.69 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/17/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/15/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $18.07 | General |
| Category: Ophthalmology | ||||||
| 07/06/2023 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $111.27 | General |
| Category: Ophthalmology | ||||||
| 03/17/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $16.11 | General |
| Category: Ophthalmology | ||||||
| 02/08/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: EYE CARE | ||||||
| 01/17/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/12/2023 | Coherus Biosciences Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: Ophthalmology | ||||||
| 01/07/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 5,596 | 16,191 | $2.4M | $1.6M |
| 2022 | 19 | 5,553 | 13,649 | $2.7M | $1.7M |
| 2021 | 18 | 5,435 | 14,155 | $3.0M | $2.0M |
| 2020 | 15 | 5,296 | 14,157 | $2.7M | $1.8M |
Total Patients
21,880
Total Services
58,152
Medicare Billing
$7.1M
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 128 | 1,102 | $1.1M | $764,175 | 70.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 477 | 2,077 | $263,883 | $174,244 | 66.0% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 361 | 1,495 | $233,596 | $108,159 | 46.3% |
| 92134 | Imaging of retina | Office | 2023 | 1,495 | 3,597 | $155,761 | $100,664 | 64.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 498 | 1,489 | $143,784 | $95,078 | 66.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 12 | 3,060 | $125,446 | $88,893 | 70.9% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 810 | 1,004 | $135,954 | $82,357 | 60.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 17 | 259 | $79,734 | $47,099 | 59.1% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 45 | 48 | $60,227 | $40,853 | 67.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 285 | 285 | $51,085 | $31,597 | 61.9% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 1,033 | 1,293 | $36,872 | $22,208 | 60.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 174 | 177 | $25,531 | $18,024 | 70.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 69 | 69 | $16,695 | $10,294 | 61.7% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 126 | 149 | $14,267 | $7,958 | 55.8% |
| 67105 | Repair of detached retina using a laser | Office | 2023 | 13 | 14 | $4,847 | $2,971 | 61.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 14 | $2,279 | $1,141 | 50.1% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 13 | 31 | $6,050 | $1,084 | 17.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 26 | 28 | $1,423 | $1,035 | 72.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 122 | 1,276 | $1.3M | $919,974 | 72.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 454 | 2,168 | $278,942 | $182,815 | 65.5% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 341 | 1,540 | $385,000 | $112,464 | 29.2% |
| 92134 | Imaging of retina | Office | 2022 | 1,459 | 3,653 | $161,896 | $104,275 | 64.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 506 | 1,423 | $140,873 | $93,926 | 66.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 16 | 362 | $116,051 | $80,624 | 69.5% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 743 | 926 | $128,535 | $75,608 | 58.8% |
About Dr. Alan Gordon, MD
Dr. Alan Gordon, MD is a Ophthalmology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1518959287.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Gordon, MD has received a total of $87,163 in payments from pharmaceutical and medical device companies, with $50,810 received in 2024. These payments were reported across 105 transactions from 18 companies. The most common payment nature is "Acquisitions" ($50,000).
As a Medicare-enrolled provider, Gordon has provided services to 21,880 Medicare beneficiaries, totaling 58,152 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Phoenix, AZ
- Active Since 08/18/2005
- Last Updated 04/04/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1518959287
Products in Payments
- EYLEA AFLIBERCEPT INJECTION (Biological) $646.42
- OZURDEX (Drug) $579.08
- EYLEA (Biological) $446.86
- Stellaris (Device) $433.04
- YUTIQ (Drug) $424.65
- EVA Ophthalmic Surgical System (Device) $319.14
- STELLARIS PC (Device) $262.38
- Vabysmo (Drug) $230.03
- Lucentis (Biological) $209.33
- EVA, combined machine (Device) $150.72
- Iluvien (Drug) $125.00
- Humira (Biological) $77.25
- VABYSMO (Drug) $48.31
- None Specified (Medical Supply) $38.80
- Syfovre (Drug) $34.18
- ACTHAR (Biological) $33.07
- Susvimo (Drug) $31.77
- Cimerli (Biological) $29.23
- LOTEMAX GEL (Drug) $21.75
- Izervay (Drug) $21.61
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Phoenix
Dr. Jordan Graff, Md, MD
Ophthalmology — Payments: $413,274
Ophthalmology $413,274
Dr. Christopher Fecarotta, Md, MD
Ophthalmology — Payments: $374,240
Ophthalmology $374,240
Dr. Pravin Dugel
Ophthalmology — Payments: $366,469
Ophthalmology $366,469
Jung Dao, Md, MD
Ophthalmology — Payments: $266,341
Ophthalmology $266,341
Benjamin Bakall, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $130,789
Ophthalmology $130,789
Jaime Gaitan, Md, MD
Ophthalmology — Payments: $127,271
Ophthalmology $127,271